Development of an Ovine Model of Heart Transplantation Following 24-Hour Brain Stem Death

Hoe, Louise E. See; Engkilde-Pedersen, S.; Obonyo, Nchafatso G.; Wells, M.; Boon, Cindy; Bartnikowski, Nicole; Passmore, Margaret; McDonald, Charles; Black, Debra; Molenaar, Peter; Diab, Sara; Suen, Jacky Y.; Marasco, Silvana; McGiffin, David C.

doi:10.1016/j.hlc.2018.06.111

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As the use of MCS technology continues to increase exponentially, in a health service that is crumbling under the increasing ageing population, it is naïve to believe this will not impact the incidence of refractory cardiac patients requiring treatment. Our research group has developed several preclinical models investigating MCS (ventricular assist devices, VADs) [18], extra-corporeal membrane oxygenation (ECMO) [19], and HTx [20]. These are important life-saving interventions used for patients with severe cardiac damage.…”

Section: Introductionmentioning

confidence: 99%

Hurdles to Cardioprotection in the Critically Ill

Hoe

Bartnikowski

Wells

et al. 2019

IJMS

View full text Add to dashboard Cite

Cardiovascular disease is the largest contributor to worldwide mortality, and the deleterious impact of heart failure (HF) is projected to grow exponentially in the future. As heart transplantation (HTx) is the only effective treatment for end-stage HF, development of mechanical circulatory support (MCS) technology has unveiled additional therapeutic options for refractory cardiac disease. Unfortunately, despite both MCS and HTx being quintessential treatments for significant cardiac impairment, associated morbidity and mortality remain high. MCS technology continues to evolve, but is associated with numerous disturbances to cardiac function (e.g., oxidative damage, arrhythmias). Following MCS intervention, HTx is frequently the destination option for survival of critically ill cardiac patients. While effective, donor hearts are scarce, thus limiting HTx to few qualifying patients, and HTx remains correlated with substantial post-HTx complications. While MCS and HTx are vital to survival of critically ill cardiac patients, cardioprotective strategies to improve outcomes from these treatments are highly desirable. Accordingly, this review summarizes the current status of MCS and HTx in the clinic, and the associated cardiac complications inherent to these treatments. Furthermore, we detail current research being undertaken to improve cardiac outcomes following MCS/HTx, and important considerations for reducing the significant morbidity and mortality associated with these necessary treatment strategies.

show abstract

Section: Introductionmentioning

confidence: 99%